Insider Transactions
| Date | Name | Title | Type | Filing | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Oct 01, 2020 | Director | Open market or private purchase of non-derivative or derivative security | Form 4 | 1,500 | $14.28 | 35,467 | |
| Oct 02, 2020 | Chief Medical Officer | Other acquisition or disposition | Form 4 | -- | -- | 20 | |
| Oct 02, 2020 | Chief Financial Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 11,000 | $2.45 | 218,179 | |
| Oct 02, 2020 | Chief Financial Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 11,000 | -- | 6,892 | |
| Oct 05, 2020 | Director, Chairman & CEO | Other acquisition or disposition | Form 4 | -- | -- | 64,895 | |
| Oct 09, 2020 | Chief People Officer | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Form 4 | 5,510 | $15.12 | 141,111 | |
| Oct 09, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 43,700 | $8.61 | 564,507 | |
| Oct 09, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 75,000 | $12.28 | 639,507 | |
| Oct 09, 2020 | Chief Science Officer | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | Form 4 | 75,000 | $9.03 | 714,507 | |
| Oct 09, 2020 | Chief Science Officer | Open market or private sale of non-derivative or derivative security | Form 4 | 193,700 | $15.03 | 520,807 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.